Objective: No organized cervical screening programs or national cervical cytology quality control standards currently exist in China. This study reported cervical cytology performance in China's largest independent laboratory with accreditation from the College of American Pathologists. Design: Results from over 2 million Papanicolaou (Pap) tests by the KingMed Diagnostics Laboratory were categorized according to The Bethesda System (TBS) from 2007 and 2014. Pap reports and histopathologic follow-up results of squamous cell carcinomas (SCC) were analyzed. Results: Data on 676,445 conventional Pap smears (CPS) and 1,696,284 liquid-based cytology (LBC) specimens were available. Abnormality rates reported were significantly higher with LBC than with CPS in all TBS categories (p < 0.001). A total of 800 SCC cytology reports were identified, representing a laboratory SCC reporting rate of 0.0337%. The SCC reporting rate with LBC (0.0457%) was significantly higher than the reporting rate with CPS. Histopathologic invasive cervical carcinoma and cervical intraepithelial neoplasia 2/3 were diagnosed in 80.7 and 17.6% of the 119 patients with SCC Pap cytology. Conclusions: Reporting rates for most TBS categories from this CAP-accredited laboratory in China were within the CAP benchmark ranges except for low atypical glandular cell and unsatisfactory case rates. Histological follow-up results in patients with SCC cytology reports demonstrate very high specificity of SCC Pap cytology.

Keywords:
Squamous cell carcinoma, China, Histological follow-up, The Bethesda System, Papanicolaou cytology
1.
Shi JF, Qiao YL, Smith JS, et al: Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. Vaccine 2008;26(suppl 12):M53-M59.
2.
Li J, Kang LN, Qiao YL: Review of the cervical cancer burden in Mainland China. Asian Pac J Cancer Prev 2011;12:1149-1153.
3.
Zheng B, Austin RM, Liang X, et al: Bethesda system reporting rates for conventional Papanicolaou tests and liquid-based cytology in a large Chinese College of American Pathologists-certified independent medical laboratory: analysis of 1394389 Papanicolaou test reports. Arch Pathol Lab Med 2015;139:373-377.
4.
Zheng B, Austin RM, Liang X, et al: PPV of an HSIL cervical cytology result in China's largest CAP-certified laboratory. J Am Soc Cytopathol 2015;4:84-89.
5.
Eversole GM, Moriarty AT, Schwartz MR, et al: Practices of participants in the College of American Pathologists Interlaboratory Comparison Program in cervicovaginal cytology, 2006. Arch Pathol Lab Med 2010;134:331-335.
6.
Allen TC, Hammond MEH, Robboy SJ: Quality and the College of American Pathologists. Arch Pathol Lab Med 2011;135:1441.
7.
Berstein SJ, Sanchez-Ramos L, Ndubisi B: Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001;185:308-317.
8.
Nance KV: Evolution of Pap testing at a community hospital - a ten year experience. Diagn Cytopathol 2007;35:148-153.
9.
Hutchinson ML, Isenstein LM, Goodman AK, et al: Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep processor. Am J Clin Pathol 1994;101:215-219.
10.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM; Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
11.
Zhao F, Lewkowitz AK, Hu S, Chen F, Li L, Zhang Q, Wu R, Li C, Wei L, Xu A, Zhang W, Pan Q, Zhang X, Belinson JL, Sellors JW, Smith JS, Qiao Y, Franceschi S: Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer 2012;131:2929-2938.
12.
Pan Q, Hu S, Guo H, Zhang W, Zhang X, Chen W, Cao J, Jiang Y, Zhao F, Qiao Y: Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China. Gynecol Oncol 2014;133:172-179.
13.
International Collaboration of Epidemiological Studies of Cervical Cancer: Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2006;120:885-891.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.